Non-interventional study of the clinical course of mild to moderate IPF under therapy with Esbriet(R)

Non-interventional study of the clinical course of mild to moderate IPF under therapy with Esbriet(R) - AER plus

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006040

Enrollment

100

Registered

2014-05-15

Start date

2014-06-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate Idiopathic Pulmonary Fibrosis in adults J84.1

Interventions

Group 1: Observation of the application of Esbriet(R) (Pirfenidone) in the treatment of mild to moderate IPF in adult patients.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: According to SPMC

Exclusion criteria

Exclusion criteria: According to SPMC

Design outcomes

Primary

Measure	Time frame
Clinical outcome of patients suffering from a mild till moderate IPF after a one-year-therapie with Pirfenidon. The evaluation of the clinical outcome takes place by capturing and evaluating lung function parameters, blood gas analysis and others.	—

Secondary

Measure	Time frame
not specified/N/A	—

Countries

Germany

Contacts

Public ContactDana Dirlam

IQVIA Commercial GmbH & Co. OHG

dana.dirlam@iqvia.com+49 3342 42 68 9 21

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026